

**BioCurex Inc.**

Ste. 215, 7080 River Rd.  
Richmond BC V6X 1X5

Tel: (604) 207-9150  
(866) 884-8669  
Fax: (604) 207-9165

Mgmt: Ricardo Moro-Vidal

R&D:

www.biocurex.com info@biocurex.com

Est: Rev: Staff:

- Drug Developm't
- Commercializ'n
- Cancer

**Profile** 21-11

Stock Symbol:

We are a biotechnology company focused on developing and commercializing products for early cancer diagnosis using a proprietary blood test based on the RECAF™ tumor marker. The test can be carried out in clinical labs or at the doctor's office in a 'rapid test' format similar to pregnancy tests available in drug stores.

**Products and Services**

We have developed and own, royalty-free, the proprietary technology related to the RECAF™ marker, with patents granted in the United States, Australia, Norway, Europe and China and patents applied for and pending in other major worldwide markets. Recently, our subsidiary OncoPet Diagnostics Inc. launched a veterinary version of the RECAF™ blood test for companion animals.

**Canadian Manufacturing Facilities:****Biogen Idec Canada**

90 Burnhamthorpe Rd., West, Ste. 1100  
Mississauga ON L5B 3C3

Tel: (905) 804-1444

Fax: (905) 897-3222

Mgmt: Karen Brennen

R&D:

www.biogenidec.com biogenideccanada@biogenidec.com

Est: 1998 - Private Rev: 55.00 Staff: 45

- Rx/Prescription
- Immunology
- CNS/Neurology
- Dermatology
- Oncology
- Autoimmune
- Rheumatology
- G.I. Diseases

**Profile** 11-21

Stock Symbol: Nasdaq: biib

Parent company, Biogen Idec Inc. is headquartered in Cambridge, MA, U.S.A. In 1996 the company introduced AVONEX® for treatment of Multiple Sclerosis. Idec intro- duced Rituxan® for treatment of non-Hodgkin's lymphoma in 1999. Also working on drugs in these areas: dermatology, neurology, oncology, gastroenterology, rheumatology.

**Products and Services**

Numerous products in the research and development phase, pertaining to the above mentioned areas, notably TYSABRI® (natalizumab) for the treatment of multiple sclerosis.

**Canadian Manufacturing Facilities:****Bioniche Life Sciences Inc.**

231 Dundas St. East  
PO Box 1570  
Belleville ON K8N 5J2

Mgmt: Ms. Jennifer Shea

R&D: Dr. Dragan Rogan

www.bioniche.com info@bioniche.com

Est: 1979 - Public Rev: 40.00 Staff: 235 (est)

- Research
- Oncology
- Anti-inflammatory

**Profile** 11-21

Stock Symbol: TSX: BNC

Bioniche is a fully integrated Canadian bio-pharma company engaged in R&D, production and commercialization of proprietary technologies for human & animal health markets worldwide. Bioniche Therapeutics is responsible for scientific disc in-vitro & in-vivo pre-clinical R&D of human health products derived from proprietary technologies, clinical studies.

**Products and Services**

Suplasyn® for treatment of Osteoarthritis; Cystistat® for treatment of Interstitial Cystitis, a painful, debilitating bladder condition. Primary focus of R&D programme is cancer, immunomodulation and inflammation.

**Canadian Manufacturing Facilities:****Bionique Testing Laboratories, Inc.**

156 Fay Brook Drive  
Saranac Lake NY 12983

USA

Mgmt: Mr. Daniel Lundin

R&D: Dr. Shayn Armstrong

www.bionique.com bionique@northnet.org

Est: 1990 - Private Rev: Staff: 18

- Mycoplasma Test
- Microbiol Test
- Cell Culture
- AnalyticLabService
- Sterility Testing
- Lot ReleaseTesting

**Profile** 11-21

Stock Symbol:

Bionique Testing Laboratories, Inc. is a leading global organization specializing in Mycoplasma testing of cell cultures, raw materials and biopharmaceutical products. For over two decades, Bionique has been providing mycoplasma testing services, diagnostic kits and consultation to biopharmaceutical companies, media/sera manufacturers and research institutions.

**Products and Services**

See ad pg. 35

Bionique's core servcies include direct culture, indicator cell lines, DNA-fluorochrome assays, mycoplasmastasis studies, antibiotic sensitivity profiles, mycoplasma elimination, validation studies and contractual R&D services. Products include the exclusive CELLshipper® Mycoplasma Detection Kit and Mycoplasma Control Slides. The facility meets cGMP standards and complies with Federal regulations 21 parts 210 and 211.

**Canadian Manufacturing Facilities:**